Build status - In Progress

Inhaled AR-501 in Adults with P. Aeruginosa Infected Cystic Fibrosis Subjects

Inhaled AR-501 in Adults with P. Aeruginosa Infected Cystic Fibrosis Subjects
Recruiting
18 years - 49 years
All
Phase 1
5 participants needed
1 Location

Brief description of study

This is a study of AR-501 (gallium citrate) solution, administered via inhalation, in adults with P. aeruginosa infected cystic fibrosis (CF). The study will evaluate the safety and pharmacokinetic (PK) and efficacy of repeat administrations of inhaled AR-501 solution in P. aeruginosa infected CF.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: P. Aeruginosa Infected Cystic Fibrosis Subjects
  • Age: 18 years - 49 years
  • Gender: All

Male and Female, P. Aeruginosa Infected Cystic Fibrosis Subjects, Age 18-49

Updated on 04 Aug 2024. Study ID: 849607

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center